> top > docs > PubMed:25267524 > annotations

PubMed:25267524 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 138-714 BACKGROUND denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
T2 734-1676 METHODS denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later.
T3 1689-2070 CONCLUSIONS denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-125 Sentence denotes Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
TextSentencer_T2 126-137 Sentence denotes BACKGROUND:
TextSentencer_T3 138-214 Sentence denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents.
TextSentencer_T4 215-325 Sentence denotes Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma.
TextSentencer_T5 326-436 Sentence denotes However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy.
TextSentencer_T6 437-575 Sentence denotes A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma.
TextSentencer_T7 576-714 Sentence denotes We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
TextSentencer_T8 715-733 Sentence denotes CASE PRESENTATION:
TextSentencer_T9 734-935 Sentence denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
TextSentencer_T10 936-1082 Sentence denotes After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks.
TextSentencer_T11 1083-1158 Sentence denotes Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
TextSentencer_T12 1159-1293 Sentence denotes Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma.
TextSentencer_T13 1294-1410 Sentence denotes Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria.
TextSentencer_T14 1411-1447 Sentence denotes His kidney function remained stable.
TextSentencer_T15 1448-1519 Sentence denotes Kidney biopsy findings were consistent with thrombotic microangiopathy.
TextSentencer_T16 1520-1608 Sentence denotes Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved.
TextSentencer_T17 1609-1676 Sentence denotes Due to progression of multiple myeloma, he died a few months later.
TextSentencer_T18 1677-1688 Sentence denotes CONCLUSION:
TextSentencer_T19 1689-2070 Sentence denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.
T1 0-125 Sentence denotes Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
T2 126-137 Sentence denotes BACKGROUND:
T3 138-214 Sentence denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents.
T4 215-325 Sentence denotes Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma.
T5 326-436 Sentence denotes However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy.
T6 437-575 Sentence denotes A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma.
T7 576-714 Sentence denotes We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
T8 715-733 Sentence denotes CASE PRESENTATION:
T9 734-935 Sentence denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
T10 936-1082 Sentence denotes After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks.
T11 1083-1158 Sentence denotes Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
T12 1159-1293 Sentence denotes Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma.
T13 1294-1410 Sentence denotes Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria.
T14 1411-1447 Sentence denotes His kidney function remained stable.
T15 1448-1519 Sentence denotes Kidney biopsy findings were consistent with thrombotic microangiopathy.
T16 1520-1608 Sentence denotes Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved.
T17 1609-1676 Sentence denotes Due to progression of multiple myeloma, he died a few months later.
T18 1677-1688 Sentence denotes CONCLUSION:
T19 1689-2070 Sentence denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-125 Sentence denotes Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
T2 126-137 Sentence denotes BACKGROUND:
T3 138-214 Sentence denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents.
T4 215-325 Sentence denotes Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma.
T5 326-436 Sentence denotes However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy.
T6 437-575 Sentence denotes A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma.
T7 576-714 Sentence denotes We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
T8 715-733 Sentence denotes CASE PRESENTATION:
T9 734-935 Sentence denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
T10 936-1082 Sentence denotes After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks.
T11 1083-1158 Sentence denotes Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
T12 1159-1293 Sentence denotes Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma.
T13 1294-1410 Sentence denotes Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria.
T14 1411-1447 Sentence denotes His kidney function remained stable.
T15 1448-1519 Sentence denotes Kidney biopsy findings were consistent with thrombotic microangiopathy.
T16 1520-1608 Sentence denotes Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved.
T17 1609-1676 Sentence denotes Due to progression of multiple myeloma, he died a few months later.
T18 1677-1688 Sentence denotes CONCLUSION:
T19 1689-2070 Sentence denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.
T1 0-125 Sentence denotes Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
T2 126-137 Sentence denotes BACKGROUND:
T3 138-214 Sentence denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents.
T4 215-325 Sentence denotes Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma.
T5 326-436 Sentence denotes However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy.
T6 437-575 Sentence denotes A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma.
T7 576-714 Sentence denotes We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
T8 715-733 Sentence denotes CASE PRESENTATION:
T9 734-935 Sentence denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
T10 936-1082 Sentence denotes After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks.
T11 1083-1158 Sentence denotes Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
T12 1159-1293 Sentence denotes Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma.
T13 1294-1410 Sentence denotes Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria.
T14 1411-1447 Sentence denotes His kidney function remained stable.
T15 1448-1519 Sentence denotes Kidney biopsy findings were consistent with thrombotic microangiopathy.
T16 1520-1608 Sentence denotes Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved.
T17 1609-1676 Sentence denotes Due to progression of multiple myeloma, he died a few months later.
T18 1677-1688 Sentence denotes CONCLUSION:
T19 1689-2070 Sentence denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 308-324 HP_0006775 denotes multiple myeloma
T2 558-574 HP_0006775 denotes multiple myeloma
T3 697-713 HP_0006775 denotes multiple myeloma

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1008-1014 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T2 1415-1421 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T3 1101-1106 http://purl.obolibrary.org/obo/UBERON_0001977 denotes serum

PubCasesHPO

Id Subject Object Predicate Lexical cue
TI1 108-124 HP:0006775 denotes multiple myeloma
AB1 308-324 HP:0006775 denotes multiple myeloma
AB2 558-574 HP:0006775 denotes multiple myeloma
AB3 697-713 HP:0006775 denotes multiple myeloma
AB4 767-779 HP:0000822 denotes hypertension
AB5 804-820 HP:0006775 denotes multiple myeloma
AB6 1002-1021 HP:0001919 denotes acute kidney injury
AB7 1276-1292 HP:0006775 denotes multiple myeloma
AB8 1360-1365 HP:0000969 denotes edema
AB9 1370-1382 HP:0000822 denotes hypertension
AB10 1398-1409 HP:0000093 denotes proteinuria
AB11 1570-1581 HP:0000093 denotes proteinuria
AB12 1586-1598 HP:0000822 denotes hypertension
AB13 1631-1647 HP:0006775 denotes multiple myeloma

PubCasesORDO

Id Subject Object Predicate Lexical cue
TI1 108-124 ORDO:29073 denotes multiple myeloma
AB1 308-324 ORDO:29073 denotes multiple myeloma
AB2 558-574 ORDO:29073 denotes multiple myeloma
AB3 697-713 ORDO:29073 denotes multiple myeloma
AB4 804-820 ORDO:29073 denotes multiple myeloma
AB5 1276-1292 ORDO:29073 denotes multiple myeloma
AB6 1631-1647 ORDO:29073 denotes multiple myeloma

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1101-1106 http://purl.obolibrary.org/obo/UBERON_0001977 denotes serum
PD-UBERON-AE-B_T2 899-917 http://purl.obolibrary.org/obo/UBERON_0002390 denotes hematopoietic stem
PD-UBERON-AE-B_T3 953-971 http://purl.obolibrary.org/obo/UBERON_0002390 denotes hematopoietic stem
PD-UBERON-AE-B_T4 1193-1211 http://purl.obolibrary.org/obo/UBERON_0002390 denotes hematopoietic stem
PD-UBERON-AE-B_T5 1008-1014 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T6 1415-1421 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T7 1448-1454 http://purl.obolibrary.org/obo/UBERON_0002113 denotes Kidney